Stage 1 of 8
Pipeline monitoring
Agents watch FDA sources continuously for new drugs, indications, generics, biosimilars, and label changes, each with its source attached.
Platform
How a drug moves through CliniVantIQ
CliniVantIQ takes a drug from the moment the FDA approval letter arrives to its place on the formulary, ready for claims and for the patients who need it.
The lifecycle, stage by stage
Eight stages, one record
Each stage hands work to the next. The clinical, utilization management, and financial reviews run in parallel, on the same drug.
Stage 2 of 8
Classification and routing
Every product is classified the same way every time and reaches every team that needs it, at once.
Stages 3 to 5 run in parallel, on the same drug record
Stage 3 of 8
P&T clinical review
Monographs and class review updates are drafted from cited sources for pharmacists to review and finalize.
Stage 4 of 8
Formulary financial review
Placement scenarios show which products and pricing arrangements a new drug could affect.
Stage 5 of 8
Utilization management
Prior authorization, step therapy, and quantity and age limits are stored as structured criteria linked to the drugs they govern.
Stage 6 of 8
Value placement decision
Clinical and financial inputs come together in one view, and the rationale is recorded as the decision is made.
Stage 7 of 8
Formulary coding and rules
Rules can be built on any drug attribute and on cost, with conflicts detected and explained rather than hidden.
Stage 8 of 8
Layering and outputs
One base drug list, client and group layers on top, and every document, search tool, and claims file generated from the same data.
Screens from the CliniVantIQ demo platform. Drug names, dates, figures and people are illustrative and shown for demonstration only.
The decision record
Why is this drug here? The answer takes seconds.
Every coded formulary entry traces back through the placement decision, the P&T recommendation, the utilization management criteria, and the financial scenarios to the FDA source that started it. That record answers the questions clients, auditors, and regulators ask: why is this drug here, who decided, when, and on what basis.
Coded formulary entry
Arvelza 40 mg/0.4 mL, Tier 2 preferred, step therapy applies
On the base drug list and carried into three client layers. Coded from the placement decision below.
Value placement decision
Prefer the biosimilar at Tier 2; the reference product moves to Tier 3
The clinical recommendation and the financial scenario were reviewed together, and the rationale was recorded as the decision was made.
P&T recommendation
Clinically equivalent; add to the class review
Monograph drafted from cited sources and finalized by a pharmacist.
UM criteria
Step therapy: biosimilar first for new starts
Structured, versioned criteria linked to the products they govern.
Financial scenario
Scenario B of 3 selected
Placement options and the products they affect, modeled before the decision.
Classification and routing
Biosimilar, in an existing therapeutic class
Classified the same way every time and routed to P&T, drug list management, and clinical programs at once.
FDA source
FDA approval letter, attached to the record
Found by pipeline monitoring and linked here, so anyone can open the document that started it all.
Be first in line
Join the waitlist for early access, or book a 20-minute intro call if you're ready to talk now.
Launching mid December 2026. Join the waitlist for early access.